Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Clinical trial NCT01282463 · COMPLETED

Trial details

NCT number: NCT01282463
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma of Urinary Tract Urethral Carcinoma Carcinoma of Ureter Carcinoma of Renal Pelvis

Start date: 2011-04-01
Primary completion: 2015-02-01
Enrollment: 148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.